Furthermore, multiple studies have reported enhancement of chemotherapy and rituximab sensitivity in human lymphoma/leukemia cells and xenografts when combined with survivin inhibition [18, 39, 47]; however, trials of survivin inhibition in dogs with neoplasia have yet to be reported in the peer-reviewed literature. Here, BIRC5 is linked to lymphoma.